Warner E, Plewes D B, Shumak R S, Catzavelos G C, Di Prospero L S, Yaffe M J, Goel V, Ramsay E, Chart P L, Cole D E, Taylor G A, Cutrara M, Samuels T H, Murphy J P, Murphy J M, Narod S A
Division of Medical Oncology, Department of Medical Biophysics, and Centre for Research in Women's Health, Toronto, Ontario, Canada.
J Clin Oncol. 2001 Aug 1;19(15):3524-31. doi: 10.1200/JCO.2001.19.15.3524.
Recommended surveillance for BRCA1 and BRCA2 mutation carriers includes regular mammography and clinical breast examination, although the effectiveness of these screening techniques in mutation carriers has not been established. The purpose of the present study was to compare breast magnetic resonance imaging (MRI) with ultrasound, mammography, and physical examination in women at high risk for hereditary breast cancer.
A total of 196 women, aged 26 to 59 years, with proven BRCA1 or BRCA2 mutations or strong family histories of breast or ovarian cancer underwent mammography, ultrasound, MRI, and clinical breast examination on a single day. A biopsy was performed when any of the four investigations was judged to be suspicious for malignancy.
Six invasive breast cancers and one noninvasive breast cancer were detected among the 196 high-risk women. Five of the invasive cancers occurred in mutation carriers, and the sixth occurred in a woman with a previous history of breast cancer. The prevalence of invasive or noninvasive breast cancer in the 96 mutation carriers was 6.2%. All six invasive cancers were detected by MRI, all were 1.0 cm or less in diameter, and all were node-negative. In contrast, only three invasive cancers were detected by ultrasound, two by mammography, and two by physical examination. The addition of MRI to the more commonly available triad of mammography, ultrasound, and breast examination identified two additional invasive breast cancers that would otherwise have been missed.
Breast MRI may be superior to mammography and ultrasound for the screening of women at high risk for hereditary breast cancer.
对于携带BRCA1和BRCA2基因突变的患者,推荐的监测手段包括定期进行乳房X线摄影和临床乳腺检查,尽管这些筛查技术在突变携带者中的有效性尚未得到证实。本研究的目的是比较乳腺磁共振成像(MRI)与超声、乳房X线摄影及体格检查在遗传性乳腺癌高危女性中的应用效果。
共有196名年龄在26至59岁之间、已证实携带BRCA1或BRCA2基因突变或有乳腺癌或卵巢癌家族史的女性,在同一天接受了乳房X线摄影、超声、MRI及临床乳腺检查。当四项检查中的任何一项被判定为可疑恶性病变时,即进行活检。
在这196名高危女性中,共检测出6例浸润性乳腺癌和1例非浸润性乳腺癌。其中5例浸润性癌发生在突变携带者中,第6例发生在一名有乳腺癌病史的女性身上。96名突变携带者中浸润性或非浸润性乳腺癌的患病率为6.2%。所有6例浸润性癌均由MRI检测出,所有肿瘤直径均在1.0 cm或以下,且均无淋巴结转移。相比之下,超声检测出3例浸润性癌,乳房X线摄影检测出2例,体格检查检测出2例。在更常用的乳房X线摄影、超声和乳腺检查三联检查基础上增加MRI检查,又发现了另外2例浸润性乳腺癌,否则这些病例将会被漏诊。
乳腺MRI在筛查遗传性乳腺癌高危女性方面可能优于乳房X线摄影和超声。